Strategic Alliance and Joint Development with the GSK Group
First written in FY2016. 1 of 2 entries say "Reframed", first in FY2018-Q2. Latest entry: FY2018-Q2.
No other company in this theme has enough history to compare yet.
- FY2018-Q2ReframedAnnual report
「On 21 September of this year, we revised the comprehensive agreement with the GlaxoSmithKline Group concerning the biopharmaceutical business. For the enzyme replacement therapy for Fabry disease, the GlaxoSmithKline Group returned to us the option to conduct joint development in the Asia-Pacific region and co-promotion in those regions and Japan, which it had retained. For the enzyme replacement therapy for Hunter syndrome, the GSK Group returned to us all rights it had retained.」
The comprehensive agreement with the GSK Group was revised, and the option covering certain regions for the Fabry disease enzyme replacement therapy and all rights concerning the Hunter syndrome enzyme replacement therapy were returned to the company. - FY2016First statedAnnual report
「In December 2009, we entered into a capital and comprehensive agreement with the GSK Group concerning pharmaceutical development and sales (the “Agreement”). As of the end of the consolidated fiscal year under review, GlaxoSmithKline plc (“GSK plc”) held 24.63% of our issued shares through its subsidiary Glaxo Group Limited (“GGL”), and we were an equity-method affiliate of GSK plc.」
The company stated that it would maintain its relationship with the GSK Group, including the capital partnership, joint development and sales partnership for rare disease pharmaceuticals, and region-specific development responsibilities.